G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated ...

RAPT Therapeutics, Inc.’s RAPT share price has surged by 16.79%, which has investors questioning if this is right time to ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for RAPT Therapeutics in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju now expects that ...

C-X-C motif chemokine-10, epidermal growth factor, vascular cell adhesion molecule-1, tumour necrosis factor (TNF)-α converting enzyme, soluble TNF receptors 1 and 2, α1-antichymotrypsin and decreased ...

Herpesvirus-encoded microRNAs (v-miRNAs) play a crucial role in modulating host cellular processes to promote viral persistence, immune evasion, and pathogenesis. These v-miRNAs function by targeting ...

Chemokine receptors are GPCRs that regulate chemotactic migration of a wide variety of cells including immune and cancer cells. Most chemokine receptors contain features associated with the ability to ...